To evaluate whether the survival benefit of ICIs therapy in patients with PAPPA2‐Mut was simply resulted from the general prognostic impact of PAPPA2 mutation, we further assessed the PFS and OS difference between PAPPA2‐Mut and PAPPA2‐WT patients with NSCLC or SKCM in TCGA database (Figure S3). This evidence concerns the gene PAPPA2 and non-small cell lung carcinoma.